
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is developing novel precision oncology therapies based on their proprietary Trans-Arterial Micro-Perfusion (TAMP) platform, which aims to improve therapeutic outcomes for cancer patients while minimizing toxicities. Their lead drug candidate, RenovoGem, is in a Phase 3 registration trial for pancreatic cancer and has potential in other indications. The company is making progress in commercialization of its FDA-cleared RenovoCath medical device, and with the addition of several new active commercial cancer centers, strong revenue growth is expected in the coming years. Despite some risks, the current valuation of RenovoRx is attractive, with a potential for high rewards in the billion-dollar market.
Bears say
RenovoRx is a clinical-stage biopharmaceutical company that has made progress in its clinical drug development and RenovoCath commercialization. However, with a market potential of only ~billion dollars, and pancreatic cancer having a 5-year combined overall survival rate of 12%, it is uncertain if the TIGeR-PaC study will be successful in providing a significant improvement in overall survival. Additionally, the recent appointment of a new CFO suggests that the company may be facing financial challenges that could negatively impact its future performance.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares